CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. Market Share Analysis
3.6. Value Chain Analysis
3.7. Regulatory Guidelines
3.8. Patent Landscape
CHAPTER 4: MEDICAL ISOTOPE MARKET, BY TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Stable Isotopes
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Radioisotopes
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: MEDICAL ISOTOPE MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Diagonestic
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Nuclear Therapy
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: MEDICAL ISOTOPE MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diagnostic Centers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Research Institutes
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: MEDICAL ISOTOPE MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Type
7.2.3. Market size and forecast, by Application
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Type
7.2.5.1.2. Market size and forecast, by Application
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Type
7.2.5.2.2. Market size and forecast, by Application
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Type
7.2.5.3.2. Market size and forecast, by Application
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Type
7.3.3. Market size and forecast, by Application
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Type
7.3.5.1.2. Market size and forecast, by Application
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. UK
7.3.5.2.1. Market size and forecast, by Type
7.3.5.2.2. Market size and forecast, by Application
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. France
7.3.5.3.1. Market size and forecast, by Type
7.3.5.3.2. Market size and forecast, by Application
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Russia
7.3.5.4.1. Market size and forecast, by Type
7.3.5.4.2. Market size and forecast, by Application
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Italy
7.3.5.5.1. Market size and forecast, by Type
7.3.5.5.2. Market size and forecast, by Application
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Type
7.3.5.6.2. Market size and forecast, by Application
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Type
7.4.3. Market size and forecast, by Application
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Market size and forecast, by Type
7.4.5.1.2. Market size and forecast, by Application
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. Japan
7.4.5.2.1. Market size and forecast, by Type
7.4.5.2.2. Market size and forecast, by Application
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Type
7.4.5.3.2. Market size and forecast, by Application
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. South Korea
7.4.5.4.1. Market size and forecast, by Type
7.4.5.4.2. Market size and forecast, by Application
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. Australia
7.4.5.5.1. Market size and forecast, by Type
7.4.5.5.2. Market size and forecast, by Application
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Type
7.4.5.6.2. Market size and forecast, by Application
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Type
7.5.3. Market size and forecast, by Application
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Type
7.5.5.1.2. Market size and forecast, by Application
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Type
7.5.5.2.2. Market size and forecast, by Application
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. UAE
7.5.5.3.1. Market size and forecast, by Type
7.5.5.3.2. Market size and forecast, by Application
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. South Africa
7.5.5.4.1. Market size and forecast, by Type
7.5.5.4.2. Market size and forecast, by Application
7.5.5.4.3. Market size and forecast, by End User
7.5.5.5. Rest of LAMEA
7.5.5.5.1. Market size and forecast, by Type
7.5.5.5.2. Market size and forecast, by Application
7.5.5.5.3. Market size and forecast, by End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Canadian Nuclear Laboratories (CNL)
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Curium
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. GE Healthcare
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Jubilant Radiopharma
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Nordion Inc.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. IBA Radiopharma Solutions
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Mallinckrodt Pharmaceuticals
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. northstar medical radioisotopes, llc
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Eczacibasi-Monrol Nuclear Products
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Isotopen Technologien München (ITM)
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments
| ※参考情報 医療用同位体とは、医療分野で利用される放射性同位体のことを指します。これらの同位体は、診断や治療、研究の目的で広く使用されており、特に核医学において重要な役割を果たしています。医療用同位体は、患者の体内での病気の評価や治療効果の測定、さらには新しい治療法の開発に寄与しています。 医療用同位体の種類には、いくつかの代表的なものがあります。例えば、テクネチウム-99mは、核医学において最も一般的に使用される同位体で、診断用イメージングのために使用されます。特に、心臓や骨、腫瘍などの病変を可視化するためのシンチグラフィーにおいてその利用が多いです。また、ヨウ素-131は甲状腺疾患の診断や治療に用いられ、特に甲状腺がんやバセドウ病の治療に効果的です。さらに、フッ素-18はポジトロン放出断層撮影（PET）のために用いられ、がんの定位や進行度の評価に役立ちます。 医療用同位体の用途は多岐にわたります。まず、診断の分野では、放射性薬剤を用いて体内の臓器や組織の機能を評価することができます。この診断法は、非侵襲的でありながら高い感度と特異性を持ち、多くの疾患を早期に発見することが可能です。また、治療の分野では、放射線治療において医療用同位体が使用されます。特に、腫瘍に直接放射線を照射することで、がん細胞を攻撃し、周囲の健康な組織への影響を最小限に抑えることができます。 医療用同位体の関連技術には、イメージング技術と治療技術が含まれます。イメージング技術としては、シンチグラフィーやPET、SPECT（単光子放射断層撮影）などがあります。これらの技術は、患者の体内で放射性同位体の分布をリアルタイムで観察することを可能にし、疾患の診断を支援します。治療技術においては、放射線療法や内部放射線療法が該当します。内部放射線療法では、放射性同位体を含む薬剤を体内に投与し、腫瘍のみに放射線を集中させることができます。 医療用同位体の製造は、専用の施設で行われ、その過程にはさまざまな技術が使用されます。サイクロトロンや原子炉などの加速器を利用して、特定の同位体を生成します。これらの施設では、放射性物質の安全な取扱いや廃棄物管理に関する厳格な規制が適用されており、患者や医療従事者の安全を確保するための措置が講じられています。 医療用同位体の供給は、国際的なレベルでの協力が重要です。多くの国々が医療用同位体の生産や供給に関与しており、需要の変動に応じた供給体制が求められています。また、新しい同位体や製造方法の研究開発が進められており、より効果的な診断法や治療法の実現が期待されています。 今後の医療用同位体の役割はますます重要になると考えられています。高齢化社会の進展や新たな疾病の出現に対応するためには、これらの同位体を用いた医療技術の進化が不可欠です。特に、個別化医療や統合医療の観点から、放射性同位体の用途はさらに拡大していくことでしょう。 このように、医療用同位体は医療現場において多くの可能性を秘めており、今後もその研究と開発が進むことが期待されています。患者に対する安全性や効果を最優先に考えながら、医療用同位体の活用は、現代医療の重要な一部として位置づけられています。 |
